Antibody and virus: Binding and neutralization

Virology

Volumn 270, Issue 1, 2000, Pages 1-3

  Burton, Dennis R ^a   Williamson, R Anthony ^a   Parren, Paul W H I ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ENVELOPE PROTEIN; FC RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ANTIGEN BINDING; BINDING AFFINITY; DENGUE VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; RABIES VIRUS; SHORT SURVEY; VIRION; VIRUS ADSORPTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS NEUTRALIZATION;

DENGUE VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RABIES VIRUS;

EID: 0034712874     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0239     Document Type: Article

References (15)

1. Connor R. I., Dinces N. B., Howell A. L., Romet-Lemonne J.-L., Pasquali J.-L., Fanger M. W. Fc receptors for IgG (FcγRs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): Studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the FcγR. Proc. Natl. Acad. Sci. USA. 88:1991;9593-9597.
2. Flamand A., Raux H., Gaudin Y., Ruigrok R. W. Mechanisms of rabies virus neutralization. Virology. 194:1993;302-313.
3. Halstead S. B. Immune enhancement of viral infection. Prog. Allergy. 31:1982;301-364.
4. Klasse P. J., Moore J. P. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J. Virol. 70:1996;3668-3677.
5. Lemon S. M., Binn L. N. Incomplete neutralization of hepatitis A virus in vitro due to lipid-associated virions. J. Gen. Virol. 66:1985;2501-2505.
6. Maruyama T., Rodriguez L. L., Jahrling P. B., Sanchez A., Khan A., Nichol S. T., Peters C. J., Parren P. W. H. I., Burton D. R. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73:1999;6024-6030.
7. Morens D. M., Halstead S. B., Marchette N. J. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb. Pathogen. 3:1987;231-237.
8. Parren P. W. H. I., Mondor I., Naniche D., Ditzel H. J., Klasse P. J., Burton D. R., Sattentau Q. J. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72:1998;3512-3519.
9. Parren P. W. H. I., Sattentau Q. J., Burton D. R. HIV-1 antibody - Debris or virion? Nature Med. 3:1997;367-368.
10. Prince A. M. Challenges for development of hepatitis C virus vaccines. FEMS Microbiol. Rev. 14:1994;273-277.
11. Raux H., Coulon P., Lafay F., Flamand A. Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing. Virology. 210:1995;400-408.
12. Sakurai H., Williamson R. A., Crowe J. E., Beeler J. A., Poignard P., Bastidas R. B., Chanock R. M., Burton D. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: Significance for subunit vaccines. J. Virol. 73:1999;2956-2962.
13. Schønning K., Lund O., Lund O. S., Hansen J. E. S. Stoichiometry of monoclonal antibody neutralization of T-cell-line-adapted human immunodeficiency virus type 1. J. Virol. 73:1999;8364-8370.
14. Sullivan N., Sun Y., Binley J., Lee J., Barbas C. F. III, Parren P. W. H. I., Burton D. R., Sodroski J. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J. Virol. 72:1998;6332-6338.
15. Wallis C., Melnick J. L. Virus aggregation as the cause of the non-neutralizable persistent fraction. J. Virol. 1:1967;478-488.